Business Context and Reporting Period
This Form 8-K Current Report was filed by Envue Medical, Inc. (formerly NanoVibronix, Inc.) on December 24, 2025. The report addresses corporate governance updates regarding the company's long-term incentive plan and reflects the company's recent name change.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions and does not contain financial performance data.
Material Changes
- Plan Amendment: The Board of Directors approved the amendment and restatement of the 2024 Long Term Incentive Plan.
- Israeli Tax Compliance: The amendment updates the definition of "Awards" to include restricted stock units to comply with specific Israeli tax laws and requirements.
- Corporate Name Change: The plan reflects updates related to the company's name change from "NanoVibronix, Inc." to "Envue Medical, Inc."
- Stockholder Approval: The filing references updates related to the First Amendment to the 2024 Long Term Incentive Plan, which was approved by stockholders on December 4, 2025.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, market outlook, or specific risk factors. The primary contingency noted is the necessity of aligning the incentive plan with Israeli tax regulations.
Key Facts for Investor Verification
- Verify the full text of the Amended and Restated 2024 Long Term Incentive Plan filed as Exhibit 10.1 to understand the specific impact on equity awards.
- Confirm the effective date and scope of the name change from NanoVibronix, Inc. to Envue Medical, Inc. across all corporate filings.
- Review the stockholder approval details from December 4, 2025, regarding the First Amendment to the incentive plan.